ProfileGDS5678 / 1424595_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 90% 89% 90% 86% 86% 88% 88% 90% 92% 90% 92% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0837890
GSM967853U87-EV human glioblastoma xenograft - Control 27.2026990
GSM967854U87-EV human glioblastoma xenograft - Control 37.2196190
GSM967855U87-EV human glioblastoma xenograft - Control 47.188689
GSM967856U87-EV human glioblastoma xenograft - Control 57.2009590
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3253686
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3876186
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7533888
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.81788
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.3244590
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.6784492
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2867790
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.6795492
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2144490